Firebrick Pharma Limited (AU:FRE)

ASX:FRE

FRE

Firebrick Pharma Limited

RESEARCH TOOLSreports

Want to see AU:FRE full AI Analyst Report?

Firebrick Pharma Limited (FRE) Price & Analysis

8 Followers

FRE Stock Chart & Stats

AU$0.05

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$0.05

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.04 - AU$0.09

Previous CloseN/A

Volume87.61K

Average Volume (3M)91.61K

Market Cap

AU$11.12M

Enterprise ValueAU$7.89M

Total Cash (Recent Filing)AU$1.44M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta-0.40

Next Earnings

Aug 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding285,198,970

10 Day Avg. Volume136,612

30 Day Avg. Volume91,607

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)8.38

Price to Sales (P/S)44.43

P/FCF Ratio-7.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageZero reported debt and a 0 debt-to-equity ratio materially reduce financial risk and interest burden. This durable strength improves flexibility to fund R&D or operations, lowers insolvency risk during cash burn, and supports access to capital on better terms if needed.

Positive Gross MarginA ~36% gross margin in 2025 indicates underlying product or pricing economics that can support profitability once fixed costs and R&D are covered or revenue scales. Durable product margins create optionality for future operating leverage if top-line stabilizes or rises.

Improving Cash BurnOperating and free cash flow remain negative but show meaningful improvement versus 2023, signaling management has reduced burn. A sustained downtrend in cash outflows extends runway and makes achieving break-even or funding transition less onerous over the coming months.

Bears Say

Sharp Revenue DeclineA ~74% year-over-year revenue collapse is structural for near-term planning: it reduces economies of scale, magnifies fixed-cost burdens, and undermines commercially validating milestones. Persistent top-line volatility impairs predictability for R&D investment and commercialization timelines.

Large Persistent LossesVery large operating losses and an extreme negative net margin indicate ongoing capital erosion. Over months this forces reliance on external funding, dilutes shareholders, constrains product development choices, and elevates the risk that operations cannot be sustained without structural revenue improvement.

Not Self-funding / Small ScaleConsistent negative OCF/FCF combined with a very small team (6 employees) signals limited internal capacity and scale to commercialize or absorb setbacks. This structural funding gap increases dependency on external capital, which can be dilutive and distract management from execution.

Firebrick Pharma Limited News

Firebrick Pharma extends Nasodine patent protection with New Zealand grant

Firebrick Pharma Limited ( ($AU:FRE) ) has shared an update. Firebrick Pharma has secured a New Zealand patent...

16d ago

FRE

Firebrick Pharma issues shares to consultant in lieu of fees

The latest update is out from Firebrick Pharma Limited ( ($AU:FRE) ). Firebrick Pharma Limited has issued 220,000...

17d ago

FRE

Firebrick Pharma Seeks ASX Quotation for Additional Shares

The latest announcement is out from Firebrick Pharma Limited ( ($AU:FRE) ). Firebrick Pharma has applied to the...

17d ago

FRE

Firebrick Pharma Plans Placement of 220,000 New Shares

Firebrick Pharma Limited ( ($AU:FRE) ) has shared an update. Firebrick Pharma Limited has notified the ASX of...

18d ago

FRE

Firebrick Pharma Options Lapse, Simplifying Capital Structure

An update from Firebrick Pharma Limited ( ($AU:FRE) ) is now available. Firebrick Pharma Limited has confirmed that...

18d ago

FRE

Firebrick Pharma Calls Virtual Meeting to Ratify Key Share and Option Issues

Firebrick Pharma Limited ( ($AU:FRE) ) has shared an update. Firebrick Pharma Limited has called a virtual general...

28d ago

FRE

Firebrick Pharma Director Increases Indirect Shareholding via On-Market Purchase

The latest announcement is out from Firebrick Pharma Limited ( ($AU:FRE) ). Firebrick Pharma Limited has disclosed a...

29d ago

FRE

Firebrick Pharma wins Canadian patent for Nasodine COVID-19 use

Firebrick Pharma Limited ( ($AU:FRE) ) has issued an announcement. Firebrick Pharma has secured Canadian acceptance of a...

1M ago

FRE

Firebrick Pharma to Brief Investors After Nasodine Approval and $1.5m Placement

The latest announcement is out from Firebrick Pharma Limited ( ($AU:FRE) ). Firebrick Pharma will host an investor...

2M ago

FRE

Firebrick Pharma ramps up Nasodine rollout and global push with new capital and hires

Firebrick Pharma Limited ( ($AU:FRE) ) has shared an announcement. Firebrick Pharma reported significant progress in the March...

2M ago

FRE

FRE FAQ

What was Firebrick Pharma Limited’s price range in the past 12 months?

Firebrick Pharma Limited lowest share price was AU$0.04 and its highest was AU$0.09 in the past 12 months.

What is Firebrick Pharma Limited’s market cap?

Firebrick Pharma Limited’s market cap is AU$11.12M.

When is Firebrick Pharma Limited’s upcoming earnings report date?

Firebrick Pharma Limited’s upcoming earnings report date is Aug 28, 2026 which is in 70 days.

How were Firebrick Pharma Limited’s earnings last quarter?

Firebrick Pharma Limited released its earnings results on Mar 04, 2026. The company reported -AU$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.005.

Is Firebrick Pharma Limited overvalued?

According to Wall Street analysts Firebrick Pharma Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Firebrick Pharma Limited pay dividends?

Firebrick Pharma Limited does not currently pay dividends.

What is Firebrick Pharma Limited’s EPS estimate?

Firebrick Pharma Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Firebrick Pharma Limited have?

Firebrick Pharma Limited has 285,198,970 shares outstanding.

What happened to Firebrick Pharma Limited’s price movement after its last earnings report?

Firebrick Pharma Limited reported an EPS of -AU$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.407%.

Which hedge fund is a major shareholder of Firebrick Pharma Limited?

Currently, no hedge funds are holding shares in AU:FRE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Firebrick Pharma Limited Stock Smart Score

Underperform

Fundamentals

Return on Equity

-140.26%

Trailing 12-Months

Asset Growth

24.27%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Firebrick Pharma Limited

Firebrick Pharma Limited, an enterprise established in 2012 and headquartered in Melbourne, Australia, is dedicated to the research, development, and market launch of Nasodine, a nasal spray treatment for the common cold, exclusively for the Australian market.